Cabergoline use and risk of fibrosis and insufficiency of cardiac valves View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2013-06-08

AUTHORS

R. De Vecchis, C. Esposito, C. Ariano

ABSTRACT

BackgroundTherapy with ergot-derivative dopamine agonists (ergot-DAs) is suspected to cause or promote the development of insufficiency and regurgitation in previously normal cardiac valves. Thus, we conducted a systematic review and meta-analysis of the literature to determine whether administration of cabergoline, i.e., an ergot-DA used to treat Parkinson’s disease (PD) or hyperprolactinemia, is associated with an increased risk of valve regurgitation compared with pharmacological regimens not comprising ergot-DAs or with no therapy.MethodsObservational studies were selected from the Pubmed and Embase databases. Studies had to have assessed the prevalence, odds, or risk of cardiac valve regurgitation in patients who underwent chronic treatment with cabergoline for PD or hyperprolactinemia compared with patients with the same diseases whose therapy did not include cabergoline or another ergot-DA. Separate meta-analyses were performed for PD and hyperprolactinemia patients.ResultsOn the basis of five studies, 634 PD patients were taking cabergoline, while 9,120 PD patients were treated with dopa/dopamine decarboxylase inhibitor, alone or associated with a non-ergot DA. Valvular regurgitation of any degree—at one cardiac valve or more —was more frequent in PD patients who were taking cabergoline compared to those treated with a non-ergot DA agent or not treated with any dopamine agonist [adjusted (inverse variance: iv) odds ratio: 7.25 95 % CI: 3.71–14.18; p < 0.0001]. On the other hand, pooled data from seven studies showed that patients with hyperprolactinemia who were taking cabergoline (n = 444) exhibited significantly higher odds of mild- to-moderate tricuspid regurgitation compared to untreated controls (n = 954) [adjusted (iv) odds ratio: 1.92 95 % CI:1.34–2.73; p = 0.0003]. No significant differences in mitral or aortic valve regurgitation were detected between hyperprolactinemic patients taking cabergoline and controls.ConclusionIn PD patients, the risk of valvular regurgitation of any grade involving one or more cardiac valves was proven to be strongly associated with cabergoline treatment. Furthermore, based on our results, hyperprolactinemic patients taking cabergoline have an increased risk of mild-to-moderate tricuspid valve regurgitation. More... »

PAGES

868-880

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00059-013-3816-0

DOI

http://dx.doi.org/10.1007/s00059-013-3816-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1004446799

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23743769


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cabergoline", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dopamine Agonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ergolines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fibrosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heart Valve Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Myocardium", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Observational Studies as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prevalence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Cardiology Unit, Presidio Sanitario Intermedio\u201cElena d\u2019Aosta\u201d, Via Cagnazzi 29, 80137, Naples, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Cardiology Unit, Presidio Sanitario Intermedio\u201cElena d\u2019Aosta\u201d, Via Cagnazzi 29, 80137, Naples, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "De Vecchis", 
        "givenName": "R.", 
        "id": "sg:person.0704361014.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704361014.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Hygiene and Preventive Medicine, Second University of Naples, Naples, Italy", 
          "id": "http://www.grid.ac/institutes/grid.9841.4", 
          "name": [
            "Institute of Hygiene and Preventive Medicine, Second University of Naples, Naples, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Esposito", 
        "givenName": "C.", 
        "id": "sg:person.01135016617.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135016617.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cardiology Unit, Presidio Sanitario Intermedio\u201cElena d\u2019Aosta\u201d, Via Cagnazzi 29, 80137, Naples, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Cardiology Unit, Presidio Sanitario Intermedio\u201cElena d\u2019Aosta\u201d, Via Cagnazzi 29, 80137, Naples, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ariano", 
        "givenName": "C.", 
        "id": "sg:person.0660263343.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660263343.51"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00108-004-1280-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010716554", 
          "https://doi.org/10.1007/s00108-004-1280-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11886-012-0245-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004287927", 
          "https://doi.org/10.1007/s11886-012-0245-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/11594940-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017287253", 
          "https://doi.org/10.2165/11594940-000000000-00000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11102-011-0339-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046383164", 
          "https://doi.org/10.1007/s11102-011-0339-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11102-010-0290-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023720417", 
          "https://doi.org/10.1007/s11102-010-0290-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf03345662", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049148417", 
          "https://doi.org/10.1007/bf03345662"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11102-008-0134-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041423268", 
          "https://doi.org/10.1007/s11102-008-0134-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00002512-200320110-00006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017175953", 
          "https://doi.org/10.2165/00002512-200320110-00006"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.mp.4002009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042780954", 
          "https://doi.org/10.1038/sj.mp.4002009"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2013-06-08", 
    "datePublishedReg": "2013-06-08", 
    "description": "BackgroundTherapy with ergot-derivative dopamine agonists (ergot-DAs) is suspected to cause or promote the development of insufficiency and regurgitation in previously normal cardiac valves. Thus, we conducted a systematic review and meta-analysis of the literature to determine whether administration of cabergoline, i.e., an ergot-DA used to treat Parkinson\u2019s disease (PD) or hyperprolactinemia, is associated with an increased risk of valve regurgitation compared with pharmacological regimens not comprising ergot-DAs or with no therapy.MethodsObservational studies were selected from the Pubmed and Embase databases. Studies had to have assessed the prevalence, odds, or risk of cardiac valve regurgitation in patients who underwent chronic treatment with cabergoline for PD or hyperprolactinemia compared with patients with the same diseases whose therapy did not include cabergoline or another ergot-DA. Separate meta-analyses were performed for PD and hyperprolactinemia patients.ResultsOn the basis of five studies, 634\u00a0PD patients were taking cabergoline, while 9,120\u00a0PD patients were treated with dopa/dopamine decarboxylase inhibitor, alone or associated with a non-ergot DA. Valvular regurgitation of any degree\u2014at one cardiac valve or more \u2014was more frequent in PD patients who were taking cabergoline compared to those treated with a non-ergot DA agent or not treated with any dopamine agonist [adjusted (inverse variance: iv) odds ratio: 7.25 95\u2009% CI: 3.71\u201314.18; p\u2009<\u20090.0001]. On the other hand, pooled data from seven studies showed that patients with hyperprolactinemia who were taking cabergoline (n\u2009=\u2009444) exhibited significantly higher odds of mild- to-moderate tricuspid regurgitation compared to untreated controls (n\u2009=\u2009954) [adjusted (iv) odds ratio: 1.92 95\u2009% CI:1.34\u20132.73; p\u2009=\u20090.0003]. No significant differences in mitral or aortic valve regurgitation were detected between hyperprolactinemic patients taking cabergoline and controls.ConclusionIn PD patients, the risk of valvular regurgitation of any grade involving one or more cardiac valves was proven to be strongly associated with cabergoline treatment. Furthermore, based on our results, hyperprolactinemic patients taking cabergoline have an increased risk of mild-to-moderate tricuspid valve regurgitation.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00059-013-3816-0", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1087175", 
        "issn": [
          "0340-9937", 
          "1615-6692"
        ], 
        "name": "Herz", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "38"
      }
    ], 
    "keywords": [
      "valve regurgitation", 
      "PD patients", 
      "Parkinson's disease", 
      "cardiac valves", 
      "hyperprolactinemic patients", 
      "dopamine agonists", 
      "valvular regurgitation", 
      "ergot derivative dopamine agonists", 
      "moderate tricuspid valve regurgitation", 
      "development of insufficiency", 
      "administration of cabergoline", 
      "more cardiac valves", 
      "risk of mild", 
      "moderate tricuspid regurgitation", 
      "aortic valve regurgitation", 
      "tricuspid valve regurgitation", 
      "risk of fibrosis", 
      "cardiac valve regurgitation", 
      "normal cardiac valves", 
      "hyperprolactinemia patients", 
      "cabergoline use", 
      "MethodsObservational study", 
      "cabergoline treatment", 
      "tricuspid regurgitation", 
      "chronic treatment", 
      "pharmacological regimens", 
      "EMBASE databases", 
      "DA agents", 
      "decarboxylase inhibitor", 
      "cabergoline", 
      "higher odds", 
      "regurgitation", 
      "patients", 
      "systematic review", 
      "hyperprolactinemia", 
      "same disease", 
      "disease", 
      "significant differences", 
      "risk", 
      "therapy", 
      "agonists", 
      "insufficiency", 
      "mild", 
      "untreated controls", 
      "odds", 
      "treatment", 
      "valve", 
      "BackgroundTherapy", 
      "regimens", 
      "mitral", 
      "fibrosis", 
      "PubMed", 
      "study", 
      "prevalence", 
      "administration", 
      "ResultsOn", 
      "control", 
      "inhibitors", 
      "review", 
      "grade", 
      "agents", 
      "differences", 
      "database", 
      "DA", 
      "use", 
      "literature", 
      "data", 
      "development", 
      "hand", 
      "degree", 
      "results", 
      "basis", 
      "ergot-DA", 
      "dopa/dopamine decarboxylase inhibitor", 
      "dopamine decarboxylase inhibitor", 
      "non-ergot DA", 
      "non-ergot DA agent", 
      "ConclusionIn PD patients"
    ], 
    "name": "Cabergoline use and risk of fibrosis and insufficiency of cardiac valves", 
    "pagination": "868-880", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1004446799"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00059-013-3816-0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23743769"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00059-013-3816-0", 
      "https://app.dimensions.ai/details/publication/pub.1004446799"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:30", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_597.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00059-013-3816-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00059-013-3816-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00059-013-3816-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00059-013-3816-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00059-013-3816-0'


 

This table displays all metadata directly associated to this object as RDF triples.

241 TRIPLES      22 PREDICATES      125 URIs      108 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00059-013-3816-0 schema:about N108d7400361f448eb10ab2950aa018a5
2 N132112ef293f4c16a7cf8d18ef9b0083
3 N16aacc25d5c24a3f9e1b61a6860dc0f2
4 N3818368277614674a609dfca6161e3fa
5 N4407e7545a0647ac9a113d5ab4b93f0a
6 N46b33926a6b8479bb95f0fcc0db7dc68
7 N4b1f8f1ded104b2a8cd16d6007631900
8 N677b33b3f9984f9b80c38039821333a2
9 N9ef5af3124b246d88cbf3e8abda5fe9c
10 Ncec002d20053464aabe233f65c910167
11 Nf4d70341551b438db64677dda872e296
12 Nfcbe17e1981d4473a7bed83a966a2cbf
13 anzsrc-for:11
14 anzsrc-for:1102
15 schema:author Nf9bf85302f1e47aaa3e15316df8bd5b8
16 schema:citation sg:pub.10.1007/bf03345662
17 sg:pub.10.1007/s00108-004-1280-x
18 sg:pub.10.1007/s11102-008-0134-2
19 sg:pub.10.1007/s11102-010-0290-z
20 sg:pub.10.1007/s11102-011-0339-7
21 sg:pub.10.1007/s11886-012-0245-2
22 sg:pub.10.1038/sj.mp.4002009
23 sg:pub.10.2165/00002512-200320110-00006
24 sg:pub.10.2165/11594940-000000000-00000
25 schema:datePublished 2013-06-08
26 schema:datePublishedReg 2013-06-08
27 schema:description BackgroundTherapy with ergot-derivative dopamine agonists (ergot-DAs) is suspected to cause or promote the development of insufficiency and regurgitation in previously normal cardiac valves. Thus, we conducted a systematic review and meta-analysis of the literature to determine whether administration of cabergoline, i.e., an ergot-DA used to treat Parkinson’s disease (PD) or hyperprolactinemia, is associated with an increased risk of valve regurgitation compared with pharmacological regimens not comprising ergot-DAs or with no therapy.MethodsObservational studies were selected from the Pubmed and Embase databases. Studies had to have assessed the prevalence, odds, or risk of cardiac valve regurgitation in patients who underwent chronic treatment with cabergoline for PD or hyperprolactinemia compared with patients with the same diseases whose therapy did not include cabergoline or another ergot-DA. Separate meta-analyses were performed for PD and hyperprolactinemia patients.ResultsOn the basis of five studies, 634 PD patients were taking cabergoline, while 9,120 PD patients were treated with dopa/dopamine decarboxylase inhibitor, alone or associated with a non-ergot DA. Valvular regurgitation of any degree—at one cardiac valve or more —was more frequent in PD patients who were taking cabergoline compared to those treated with a non-ergot DA agent or not treated with any dopamine agonist [adjusted (inverse variance: iv) odds ratio: 7.25 95 % CI: 3.71–14.18; p < 0.0001]. On the other hand, pooled data from seven studies showed that patients with hyperprolactinemia who were taking cabergoline (n = 444) exhibited significantly higher odds of mild- to-moderate tricuspid regurgitation compared to untreated controls (n = 954) [adjusted (iv) odds ratio: 1.92 95 % CI:1.34–2.73; p = 0.0003]. No significant differences in mitral or aortic valve regurgitation were detected between hyperprolactinemic patients taking cabergoline and controls.ConclusionIn PD patients, the risk of valvular regurgitation of any grade involving one or more cardiac valves was proven to be strongly associated with cabergoline treatment. Furthermore, based on our results, hyperprolactinemic patients taking cabergoline have an increased risk of mild-to-moderate tricuspid valve regurgitation.
28 schema:genre article
29 schema:inLanguage en
30 schema:isAccessibleForFree false
31 schema:isPartOf N41f7e383d600414e8a93e429d0d09e34
32 Na62cac0b80fa422084cf02ac5d39a5fa
33 sg:journal.1087175
34 schema:keywords BackgroundTherapy
35 ConclusionIn PD patients
36 DA
37 DA agents
38 EMBASE databases
39 MethodsObservational study
40 PD patients
41 Parkinson's disease
42 PubMed
43 ResultsOn
44 administration
45 administration of cabergoline
46 agents
47 agonists
48 aortic valve regurgitation
49 basis
50 cabergoline
51 cabergoline treatment
52 cabergoline use
53 cardiac valve regurgitation
54 cardiac valves
55 chronic treatment
56 control
57 data
58 database
59 decarboxylase inhibitor
60 degree
61 development
62 development of insufficiency
63 differences
64 disease
65 dopa/dopamine decarboxylase inhibitor
66 dopamine agonists
67 dopamine decarboxylase inhibitor
68 ergot derivative dopamine agonists
69 ergot-DA
70 fibrosis
71 grade
72 hand
73 higher odds
74 hyperprolactinemia
75 hyperprolactinemia patients
76 hyperprolactinemic patients
77 inhibitors
78 insufficiency
79 literature
80 mild
81 mitral
82 moderate tricuspid regurgitation
83 moderate tricuspid valve regurgitation
84 more cardiac valves
85 non-ergot DA
86 non-ergot DA agent
87 normal cardiac valves
88 odds
89 patients
90 pharmacological regimens
91 prevalence
92 regimens
93 regurgitation
94 results
95 review
96 risk
97 risk of fibrosis
98 risk of mild
99 same disease
100 significant differences
101 study
102 systematic review
103 therapy
104 treatment
105 tricuspid regurgitation
106 tricuspid valve regurgitation
107 untreated controls
108 use
109 valve
110 valve regurgitation
111 valvular regurgitation
112 schema:name Cabergoline use and risk of fibrosis and insufficiency of cardiac valves
113 schema:pagination 868-880
114 schema:productId N31e537f499774948867634eaf808fcff
115 N4691dbf5d71d4c44b0fd75874ded780e
116 Nd1a847ed1249417280659e28e2482b9f
117 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004446799
118 https://doi.org/10.1007/s00059-013-3816-0
119 schema:sdDatePublished 2022-01-01T18:30
120 schema:sdLicense https://scigraph.springernature.com/explorer/license/
121 schema:sdPublisher N965cda21702d4c06b5d8acc2705be5e0
122 schema:url https://doi.org/10.1007/s00059-013-3816-0
123 sgo:license sg:explorer/license/
124 sgo:sdDataset articles
125 rdf:type schema:ScholarlyArticle
126 N108d7400361f448eb10ab2950aa018a5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Prevalence
128 rdf:type schema:DefinedTerm
129 N132112ef293f4c16a7cf8d18ef9b0083 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Myocardium
131 rdf:type schema:DefinedTerm
132 N16aacc25d5c24a3f9e1b61a6860dc0f2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Female
134 rdf:type schema:DefinedTerm
135 N31e537f499774948867634eaf808fcff schema:name doi
136 schema:value 10.1007/s00059-013-3816-0
137 rdf:type schema:PropertyValue
138 N3818368277614674a609dfca6161e3fa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Male
140 rdf:type schema:DefinedTerm
141 N41f7e383d600414e8a93e429d0d09e34 schema:volumeNumber 38
142 rdf:type schema:PublicationVolume
143 N4407e7545a0647ac9a113d5ab4b93f0a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Cabergoline
145 rdf:type schema:DefinedTerm
146 N4691dbf5d71d4c44b0fd75874ded780e schema:name pubmed_id
147 schema:value 23743769
148 rdf:type schema:PropertyValue
149 N46b33926a6b8479bb95f0fcc0db7dc68 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Dopamine Agonists
151 rdf:type schema:DefinedTerm
152 N4b1f8f1ded104b2a8cd16d6007631900 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Ergolines
154 rdf:type schema:DefinedTerm
155 N677b33b3f9984f9b80c38039821333a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Observational Studies as Topic
157 rdf:type schema:DefinedTerm
158 N720efcbb4f5e4645833a808275ced190 rdf:first sg:person.01135016617.34
159 rdf:rest Ned9403f0124c456b8c072e1f4067371f
160 N965cda21702d4c06b5d8acc2705be5e0 schema:name Springer Nature - SN SciGraph project
161 rdf:type schema:Organization
162 N9ef5af3124b246d88cbf3e8abda5fe9c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Fibrosis
164 rdf:type schema:DefinedTerm
165 Na62cac0b80fa422084cf02ac5d39a5fa schema:issueNumber 8
166 rdf:type schema:PublicationIssue
167 Ncec002d20053464aabe233f65c910167 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Heart Valve Diseases
169 rdf:type schema:DefinedTerm
170 Nd1a847ed1249417280659e28e2482b9f schema:name dimensions_id
171 schema:value pub.1004446799
172 rdf:type schema:PropertyValue
173 Ned9403f0124c456b8c072e1f4067371f rdf:first sg:person.0660263343.51
174 rdf:rest rdf:nil
175 Nf4d70341551b438db64677dda872e296 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Risk Factors
177 rdf:type schema:DefinedTerm
178 Nf9bf85302f1e47aaa3e15316df8bd5b8 rdf:first sg:person.0704361014.79
179 rdf:rest N720efcbb4f5e4645833a808275ced190
180 Nfcbe17e1981d4473a7bed83a966a2cbf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Humans
182 rdf:type schema:DefinedTerm
183 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
184 schema:name Medical and Health Sciences
185 rdf:type schema:DefinedTerm
186 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
187 schema:name Cardiorespiratory Medicine and Haematology
188 rdf:type schema:DefinedTerm
189 sg:journal.1087175 schema:issn 0340-9937
190 1615-6692
191 schema:name Herz
192 schema:publisher Springer Nature
193 rdf:type schema:Periodical
194 sg:person.01135016617.34 schema:affiliation grid-institutes:grid.9841.4
195 schema:familyName Esposito
196 schema:givenName C.
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135016617.34
198 rdf:type schema:Person
199 sg:person.0660263343.51 schema:affiliation grid-institutes:None
200 schema:familyName Ariano
201 schema:givenName C.
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660263343.51
203 rdf:type schema:Person
204 sg:person.0704361014.79 schema:affiliation grid-institutes:None
205 schema:familyName De Vecchis
206 schema:givenName R.
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704361014.79
208 rdf:type schema:Person
209 sg:pub.10.1007/bf03345662 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049148417
210 https://doi.org/10.1007/bf03345662
211 rdf:type schema:CreativeWork
212 sg:pub.10.1007/s00108-004-1280-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1010716554
213 https://doi.org/10.1007/s00108-004-1280-x
214 rdf:type schema:CreativeWork
215 sg:pub.10.1007/s11102-008-0134-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041423268
216 https://doi.org/10.1007/s11102-008-0134-2
217 rdf:type schema:CreativeWork
218 sg:pub.10.1007/s11102-010-0290-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1023720417
219 https://doi.org/10.1007/s11102-010-0290-z
220 rdf:type schema:CreativeWork
221 sg:pub.10.1007/s11102-011-0339-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046383164
222 https://doi.org/10.1007/s11102-011-0339-7
223 rdf:type schema:CreativeWork
224 sg:pub.10.1007/s11886-012-0245-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004287927
225 https://doi.org/10.1007/s11886-012-0245-2
226 rdf:type schema:CreativeWork
227 sg:pub.10.1038/sj.mp.4002009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042780954
228 https://doi.org/10.1038/sj.mp.4002009
229 rdf:type schema:CreativeWork
230 sg:pub.10.2165/00002512-200320110-00006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017175953
231 https://doi.org/10.2165/00002512-200320110-00006
232 rdf:type schema:CreativeWork
233 sg:pub.10.2165/11594940-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017287253
234 https://doi.org/10.2165/11594940-000000000-00000
235 rdf:type schema:CreativeWork
236 grid-institutes:None schema:alternateName Cardiology Unit, Presidio Sanitario Intermedio“Elena d’Aosta”, Via Cagnazzi 29, 80137, Naples, Italy
237 schema:name Cardiology Unit, Presidio Sanitario Intermedio“Elena d’Aosta”, Via Cagnazzi 29, 80137, Naples, Italy
238 rdf:type schema:Organization
239 grid-institutes:grid.9841.4 schema:alternateName Institute of Hygiene and Preventive Medicine, Second University of Naples, Naples, Italy
240 schema:name Institute of Hygiene and Preventive Medicine, Second University of Naples, Naples, Italy
241 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...